As the race continues for marketing clearance of a therapy for hereditary angioedema, the specialty pharma firm Kos Life Sciences has put its chips on Jerini AG, of Berlin, paying the company 22 million (about US$27 million) for rights to develop, market and distribute the Phase III compound Icatibant. (BioWorld Today) Read More
